Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7164-7173

  Thamake, Sanjay I ^a   Raut, Sangram L ^a   Gryczynski, Zygmunt ^a   Ranjan, Amalendu P ^a   Vishwanatha, Jamboor K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Alendronate; Bone targeting; Bortezomib; Breast cancer; Curcumin; Nanoparticles

Indexed keywords

ACTIVE TARGETING; ALENDRONATE; ALN; BIO-IMAGING; BONE METASTASIS; BONE RESORPTION; BORTEZOMIB; BREAST CANCER; CANCER CELLS; CANCER GROWTH; CELL SURFACES; CHEMOTHERAPEUTIC AGENTS; CLINICAL OUTCOME; CONTROL GROUPS; CURCUMIN; DRUG CARRIER; DRUG ENCAPSULATION; HISTOLOGICAL ANALYSIS; IN-VITRO; IN-VIVO; MICROENVIRONMENTS; MULTI-FUNCTIONAL NANOPARTICLES; MULTIPLE MYELOMA; PLGA NANOPARTICLES; POLY LACTIC-CO-GLYCOLIC ACID; SMOOTH SURFACE; SYNERGISTIC EFFECT; THERAPEUTIC AGENTS; THERAPEUTIC EFFICIENCY; TUMOR GROWTH;

CELL MEMBRANES; DISEASES; ENCAPSULATION; NANOPARTICLES; TISSUE;

BONE;

ALENDRONIC ACID; BORTEZOMIB; CURCUMIN; NANOPARTICLE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL VIABILITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; FEMALE; MOUSE; NANOENCAPSULATION; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TUMOR GROWTH;

ALENDRONATE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; BORONIC ACIDS; BREAST NEOPLASMS; CURCUMIN; DRUG CARRIERS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASM METASTASIS; OSTEOPOROSIS; POLYGLYCOLIC ACID; PYRAZINES;

EID: 84864296921     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.026     Document Type: Article

References (41)

1. Alexis F., Pridgen E.M., Langer R., Farokhzad O.C. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010, 197:55-86.
2. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010, 37(2):S15-S29.
3. Lipton A. New strategies to prevent and manage bone complications in cancer. Clin Adv Hematol Oncol 2011, 9:42-44.
4. Low S., Kopecek J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 2012.
5. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
6. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
7. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
8. Janjan N., Lutz S.T., Bedwinek J.M., Hartsell W.F., Ng A., Pieters R.S., et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology appropriateness criteria expert panel on radiation oncology. J Palliat Med 2009, 12:417-426.
9. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
10. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
11. Green J.R., Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002, 25:S3-S9.
12. Russell R.G. Determinants of structure-function relationships among bisphosphonates. Bone 2007, 40:S21-S25.
13. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
14. Choi S.W., Kim J.H. Design of surface-modified poly(D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 2007, 122:24-30.
15. Hengst V., Oussoren C., Kissel T., Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 2007, 331:224-227.
16. Cenni E., Granchi D., Avnet S., Fotia C., Salerno M., Micieli D., et al. Biocompatibility of poly(D, L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008, 29:1400-1411.
17. Wang D., Miller S.C., Kopeckova P., Kopecek J. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 2005, 57:1049-1076.
18. Salerno M., Cenni E., Fotia C., Avnet S., Granchi D., Castelli F., et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 2010, 10:649-659.
19. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
20. Bachmeier B., Nerlich A.G., Iancu C.M., Cilli M., Schleicher E., Vene R., et al. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007, 19:137-152.
21. Jones M.D., Liu J.C., Barthel T.K., Hussain S., Lovria E., Cheng D., et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 2010, 16:4978-4989.
22. Park J., Ayyappan V., Bae E.K., Lee C., Kim B.S., Kim B.K., et al. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008, 2:317-326.
23. Sung B., Kunnumakkara A.B., Sethi G., Anand P., Guha S., Aggarwal B.B. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009, 8:959-970.
24. Bharti A.C., Takada Y., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004, 172:5940-5947.
25. Thamake S.I., Raut S.L., Ranjan A.P., Gryczynski Z., Vishwanatha J.K. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology 2011, 22:035101.
26. Mukerjee A., Vishwanatha J.K. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009, 29:3867-3875.
27. Ranjan A.P., Zeglam K., Mukerjee A., Thamake S., Vishwanatha J.K. A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging. Nanotechnology 2011, 22:295104.
28. Wang G., Kucharski C., Lin X., Uludag H. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration. J Drug Target 2010, 18:611-626.
29. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37:223-230.
30. Raut S.L., Kirthivasan B., Bommana M.M., Squillante E., Sadoqi M. The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye. Nanotechnology 2010, 21:395102.
31. Okassa L.N., Marchais H., Douziech-Eyrolles L., Herve K., Cohen-Jonathan S., Munnier E., et al. Optimization of iron oxide nanoparticles encapsulation within poly(d, l-lactide-co-glycolide) sub-micron particles. Eur J Pharm Biopharm 2007, 67:31-38.
32. Braden A., Kashyap A., Vasir J., Labhasetwar V., Vishwanatha J.K. Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells. J Biomed Nanotechnol 2007, 3:148-159.
33. Kafka E.L., Braden A., Vishwanatha J.K. Characterization of nanoparticle-mediated drug delivery to NB4: feasibility of nanoparticle use for cells in suspension and blood diseases. J Biomed Nanotechnol 2008, 4:196-202.
34. Cocquyt V., Kline W.F., Gertz B.J., Van Belle S.J., Holland S.D., DeSmet M., et al. Pharmacokinetics of intravenous alendronate. J Clin Pharmacol 1999, 39:385-393.
35. Ferrer M.L., del Monte F. Enhanced emission of nile red fluorescent nanoparticles embedded in hybrid sol-gel glasses. J Phys Chem B 2005, 109:80-86.
36. Greenspan P., Mayer E.P., Fowler S.D. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985, 100:965-973.
37. Xu P., Gullotti E., Tong L., Highley C.B., Errabelli D.R., Hasan T., et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 2009, 6:190-201.
38. Richardson P.G., Mitsiades C., Hideshima T., Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006, 57:33-47.
39. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
40. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006, 103:7829-7834.
41. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001, 7:1894-1900.